The Value of Genomic Testing: A Contingent Valuation Across Six Child- and Adult-Onset Genetic Conditions
Yan Meng, Philip M Clarke, Ilias Goranitis
Pharmacoeconomics | Springer | Published : 2021
OBJECTIVES: The aim of this study was to elicit the willingness-to-pay (WTP) for genomic testing, using contingent valuation, among people with lived experience of genetic conditions in Australia. METHODS: Parents of children with suspected mitochondrial disorders, epileptic encephalopathy, leukodystrophy, or malformations of cortical development completed a dynamic triple-bounded dichotomous choice (DC) contingent valuation. Adult patients or parents of children with suspected genetic kidney disease or complex neurological and neurodegenerative conditions completed a payment card (PC) contingent valuation. DC data were analyzed using a multilevel interval regression and a multilevel probit ..View full abstract
Awarded by National Health and Medical Research Council (NHMRC) Grant
Australian Genomics Health Alliance is funded by a National Health and Medical Research Council (NHMRC) Grant (Grant reference number 1113531) and the Australian Government's Medical Research Future Fund (MRFF). The Melbourne Genomics Health Alliance is funded by the State Government of Victoria and the 10 Alliance members. The research conducted at the Murdoch Children's Research Institute was supported by the Victorian Government's Operational Infrastructure Support Program.